Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.67 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.56 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.54 |
| ▸ | ITGAM | P11215 | 1/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900321 | 1.00 | MEN1 (0.80) | MEN1KMT2APOLBMAP3K5DNMT1 | |
| SCHEMBL3892078 | 0.90 | MEN1 (0.82) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL3892083 | 0.90 | MEN1 (0.82) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL3895477 | 0.89 | MEN1 (0.80) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL3895482 | 0.89 | MEN1 (0.80) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL13762527 | 0.89 | POLB (0.80) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL3126564 | 0.89 | POLB (0.80) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL3126558 | 0.89 | POLB (0.80) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL3126561 | 0.89 | POLB (0.80) | MEN1KMT2APOLBMAP3K5STAT3 | |
| SCHEMBL5333105 | 0.88 | POLB (0.68) | MEN1KMT2APOLBMAP3K5MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | MEN1 1562/4885KMT2A 901/4885POLB 2008/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | MEN1 2869/4885KMT2A 1020/4885POLB 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.